Mitsubishi Gas Chemical Company, Inc. and GlycoNex announced approval to commence a phase I clinical trial of SPD8 denosumab, biosimilar to Amgen’s Prolia®, from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The companies announced that the first patient has now been enrolled. The double-blind trial will compare SPD8 with Prolia® in healthy postmenopausal women, who will undergo pharmacokinetic and safety assessments.
This month Boan Biotech commenced its phase III clinical trial for its Prolia® denosumab biosimilar.
Print Page Mail Article